Regeneron Pharmaceuticals Contracts & Agreements

Amendment No (Filed With SEC on May 2, 2024)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the... (Filed With SEC on February 5, 2024)

Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under... (Filed With SEC on February 5, 2024)

First Amendment to Amended and Restated License and Collaboration Agreement by and between the Registrant and Aventis Pharmaceuticals Inc., dated May 1, 2013 (Filed With SEC on August 3, 2023)

Amendment No. 1 to Master Agreement, dated as of April 10, 2023, by and between the Registrant and Alnylam Pharmaceuticals, Inc (Filed With SEC on August 3, 2023)

Waiver and Consent, dated as of April 14, 2023, pursuant to the Amended and Restated Employment Agreement, dated as of November 14, 2008, between the Registrant and Leonard S.... (Filed With SEC on August 3, 2023)

First Amendment to the Regeneron Pharmaceuticals, Inc. Cash Incentive Bonus Plan (Filed With SEC on May 4, 2023)

Third Amended and Restated Participation Agreement, dated as of March 27, 2023, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent,... (Filed With SEC on March 29, 2023)

Third Amended and Restated Lease and Remedies Agreement, dated as of March 27, 2023, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor (Filed With SEC on March 29, 2023)

Third Amended and Restated Guaranty, dated as of March 27, 2023, made by Regeneron Pharmaceuticals, Inc., Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC,... (Filed With SEC on March 29, 2023)

Credit Agreement, dated as of December 19, 2022, by and among Regeneron Pharmaceuticals, Inc., as a borrower and guarantor; certain direct subsidiaries of Regeneron... (Filed With SEC on December 20, 2022)

Modification No. 02 to Base Agreement, dated as of August 2, 2022, by and between Regeneron Pharmaceuticals, Inc. (the "Registrant") and Advanced Technology International (Filed With SEC on November 3, 2022)

Modification No. 03 to Project Agreement, dated as of May 21, 2021, by and between the Registrant and Advanced Technology International (Filed With SEC on November 3, 2022)

Modification No. 04 to Project Agreement, dated as of July 12, 2021, by and between the Registrant and Advanced Technology International (Filed With SEC on November 3, 2022)

Modification No. 06 to Project Agreement, dated as of July 12, 2022, by and between the Registrant and Advanced Technology International (Filed With SEC on November 3, 2022)

Modification P00001 to Supply Agreement, dated as of March 9, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 3, 2022)

Modification P00002 to Supply Agreement, dated as of June 17, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 3, 2022)

Modification P00003 to Supply Agreement, dated as of July 8, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 3, 2022)

Modification P00007 to Supply Agreement, dated as of July 29, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 3, 2022)

Modification No. 0 (Filed With SEC on August 3, 2022)

Amended and Restated Immuno-Oncology License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant and Sanofi Biotechnology SAS (Filed With SEC on August 3, 2022)

Fifth Amendment to Amended and Restated License and Collaboration Agreement, dated as of June 1, 2022, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi (Filed With SEC on August 3, 2022)

Modification No. 1 to Base Agreement, dated as of January 26, 2022, by and between the Registrant and Advanced Technology International (Filed With SEC on May 4, 2022)

Modification No. 5 to Project Agreement, dated as of March 22, 2022, by and between the Registrant and Advanced Technology International (Filed With SEC on May 4, 2022)

Modification P00006 to Supply Agreement, dated as of February 24, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on May 4, 2022)

Second Amended and Restated Participation Agreement, dated as of March 2, 2022, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent,... (Filed With SEC on March 8, 2022)

Second Amended and Restated Lease and Remedies Agreement, dated as of March 2, 2022, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor (Filed With SEC on March 8, 2022)

Second Amended and Restated Guaranty, dated as of March 2, 2022, made by Regeneron Pharmaceuticals, Inc., Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC,... (Filed With SEC on March 8, 2022)

Fourth Amendment to Amended and Restated License and Collaboration Agreement, dated as of October 6, 2021, by and between the Registrant, Sanofi Biotechnology SAS, and Sanofi (Filed With SEC on February 7, 2022)

Amendment No. 1 to Credit Agreement, dated as of November 11, 2021, by and among the Registrant, as a borrower and guarantor; certain direct subsidiaries of the Registrant, as... (Filed With SEC on February 7, 2022)

First Amendment to Immuno-oncology License and Collaboration Agreement, dated as of October 6, 2021, by and between the Registrant and Sanofi Biotechnology SAS (Filed With SEC on February 7, 2022)

First Amendment to Amended and Restated Participation Agreement, dated as of October 6, 2021, by and among Old Saw Mill Holdings LLC, as lessee; the Registrant, as parent... (Filed With SEC on February 7, 2022)

Modification P00004 to Supply Agreement, dated as of July 26, 2021, by and between Regeneron Pharmaceuticals, Inc. (the "Registrant") and the U.S. Army Contracting Command, New... (Filed With SEC on November 4, 2021)

Modification P00005 to Supply Agreement, dated as of September 14, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Filed With SEC on November 4, 2021)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the... (Filed With SEC on February 8, 2021)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Second Amended and... (Filed With SEC on February 8, 2021)

Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under... (Filed With SEC on February 8, 2021)

Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to P. Roy Vagelos, M.D. under the Second... (Filed With SEC on February 8, 2021)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the... (Filed With SEC on February 8, 2021)

Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to the Registrant's non-employee directors... (Filed With SEC on February 8, 2021)

Form of performance restricted stock unit award agreement and related notice of grant for use in connection with the grant of performance restricted stock units to Leonard S.... (Filed With SEC on February 8, 2021)

Project Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International (Filed With SEC on February 8, 2021)

Modification No. 01 to Project Agreement, dated as of October 13, 2020, by and between the Registrant and Advanced Technology International (Filed With SEC on February 8, 2021)

Modification No. 02 to Project Agreement, dated as of November 17, 2020, by and between the Registrant and Advanced Technology International (Filed With SEC on February 8, 2021)

Base Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International (Filed With SEC on November 5, 2020)

Project Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International (Filed With SEC on November 5, 2020)

License Agreement, dated as of August 18, 2020, by and among the Registrant, F. Hoffman-La Roche Ltd, and Genentech, Inc (Filed With SEC on November 5, 2020)

Underwriting Agreement, dated August 7, 2020, by and among the Company, Goldman Sachs & Co. LLC, BofA Securities, Inc., and J.P. Morgan Securities LLC, as representatives of the... (Filed With SEC on August 12, 2020)

Indenture, dated August 12, 2020, between the Company and U.S. Bank National Association (Filed With SEC on August 12, 2020)

First Supplemental Indenture, dated August 12, 2020, between the Company and U.S. Bank National Association (Filed With SEC on August 12, 2020)

Amendment No. 1 to Credit Agreement, dated as of June 11, 2020, by and between the Registrant, as borrower, and Goldman Sachs Bank USA, as administrative agent (Filed With SEC on August 5, 2020)

Third Amendment to Amended and Restated License and Collaboration Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant, Sanofi... (Filed With SEC on August 5, 2020)

Praluent Cross License & Commercialization Agreement, dated as of April 5, 2020, and effective as of April 1, 2020, by and between the Registrant and Sanofi Biotechnology SAS (Filed With SEC on August 5, 2020)

Underwriting Agreement, dated as of May 26, 2020, by and among Regeneron Pharmaceuticals, Inc., Sanofi, Aventisub LLC, and BofA Securities, Inc. and Goldman Sachs & Co. LLC, as... (Filed With SEC on May 29, 2020)

Stock Repurchase Agreement, dated as of May 25, 2020, by and between Regeneron Pharmaceuticals, Inc. and Sanofi (Filed With SEC on May 29, 2020)

Amendment to the Amended and Restated Investor Agreement, dated as of May 25, 2020, by and among Regeneron Pharmaceuticals, Inc., Sanofi, Sanofi-Aventis US LLC, and Aventisub LLC (Filed With SEC on May 29, 2020)

Credit Agreement, dated as of May 25, 2020, by and among Regeneron Pharmaceuticals, Inc., as borrower; Goldman Sachs Bank USA, as administrative agent, sole bookrunner, sole lead... (Filed With SEC on May 29, 2020)

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 7, 2020)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the... (Filed With SEC on February 7, 2020)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Amended and... (Filed With SEC on February 7, 2020)

Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under... (Filed With SEC on February 7, 2020)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the... (Filed With SEC on February 7, 2020)

Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to the Registrant's non-employee directors... (Filed With SEC on February 7, 2020)

Form of performance restricted stock unit award agreement and related notice of grant for use in connection with the grant of performance restricted stock units to Leonard S.... (Filed With SEC on February 7, 2020)

Second Amendment Agreement, dated December 19, 2019, by and between Bayer HealthCare LLC and the Registrant (Filed With SEC on February 7, 2020)

Investor Agreement, dated as of April 8, 2019, by and between the Registrant and Alnylam Pharmaceuticals, Inc (Filed With SEC on August 6, 2019)

Stock Purchase Agreement, dated as of April 8, 2019, by and between the Registrant and Alnylam Pharmaceuticals, Inc (Filed With SEC on August 6, 2019)

Master Agreement, dated as of April 8, 2019, by and between the Registrant and Alnylam Pharmaceuticals, Inc (Filed With SEC on August 6, 2019)

Form of Co-Co Collaboration Agreement (Exhibit B to Master Agreement contained in Exhibit 10.4) (Filed With SEC on August 6, 2019)

Form of License Agreement (Exhibit C to Master Agreement contained in Exhibit 10.4) (Filed With SEC on August 6, 2019)

Amended and Restated Guaranty, dated as of May 2, 2019, made by Regeneron Pharmaceuticals, Inc., Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC, as... (Filed With SEC on May 3, 2019)

Amended and Restated Participation Agreement, dated as of May 2, 2019, by and among Old Saw Mill Holdings LLC, as lessee; Bank of America, N.A., as administrative agent; BA... (Filed With SEC on May 3, 2019)

Amended and Restated Lease and Remedies Agreement, dated as of May 2, 2019, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor (Filed With SEC on May 3, 2019)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the... (Filed With SEC on February 7, 2019)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Amended and... (Filed With SEC on February 7, 2019)

Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under... (Filed With SEC on February 7, 2019)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the... (Filed With SEC on February 7, 2019)

Form of restricted stock unit award agreement and related notice of grant for use in connection with the grant of restricted stock units to the Registrant's non-employee directors... (Filed With SEC on February 7, 2019)

Amended and Restated Immuno-oncology Discovery and Development Agreement, executed on January 2, 2019 and effective as of December 31, 2018, by and between the Registrant and... (Filed With SEC on February 7, 2019)

Retirement Agreement, effective as of January 5, 2018, by and between Regeneron Pharmaceuticals, Inc. and Robert J. Terifay (Filed With SEC on May 3, 2018)

Letter Agreement, dated as of January 7, 2018, by and among Regeneron Pharmaceuticals, Inc., Sanofi, sanofi-aventis US LLC, Aventis Pharmaceuticals Inc., sanofi-aventis Amrique du... (Filed With SEC on May 3, 2018)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's executive officers under the... (Filed With SEC on February 8, 2018)

Form of stock option agreement and related notice of grant for use in connection with the grant of incentive stock options to the Registrant's executive officers under the Amended... (Filed With SEC on February 8, 2018)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to P. Roy Vagelos, M.D. under the Amended and... (Filed With SEC on February 8, 2018)

Form of stock option agreement and related notice of grant for use in connection with the grant of incentive stock options to P. Roy Vagelos, M.D. under the Amended and Restated... (Filed With SEC on February 8, 2018)

Form of restricted stock award agreement and related notice of grant for use in connection with the grant of restricted stock awards to the Registrant's executive officers under... (Filed With SEC on February 8, 2018)

Form of stock option agreement and related notice of grant for use in connection with the grant of non-qualified stock options to the Registrant's non-employee directors under the... (Filed With SEC on February 8, 2018)

CONSENT AND AMENDMENT NO. 1 MEMORANDUM (Filed With SEC on February 7, 2017)

Date:February 22, 2016To:Regeneron Pharmaceuticals, Inc.777 Old Saw Mill River RoadTarrytown, NY 10591-6707Attention:Dominick AgronVP and Treasurer777 Old Saw Mill River... (Filed With SEC on May 5, 2016)

VestType (Filed With SEC on February 11, 2016)

Regeneron Pharmaceuticals, Inc.Notice of Grant of Stock OptionsID:[]and Option Agreement777 Old Saw Mill River RoadTarrytown, New York 10591[OPTIONEE NAME]OptionNumber:[][OPTIONEE... (Filed With SEC on February 11, 2016)

Date:November 15, 2015To:Regeneron Pharmaceuticals, Inc.777 Old Saw Mill River RoadTarrytown, NY 10591-6707Attention:Dominick AgronVP and Treasurer777 Old Saw Mill River... (Filed With SEC on February 11, 2016)

Vest Type (Filed With SEC on November 19, 2015)

ID: [ ] Notice of Grant of Award 777 Old Saw Mill River Road And Award Agreement Tarrytown, New York 10591 [NAME] Award Number: [ ] [ADDRESS] Plan: [ ] (Filed With SEC on November 19, 2015)

IMMUNO-ONCOLOGY DISCOVERY AND DEVELOPMENT AGREEMENT By and Between SANOFI BIOTECHNOLOGY SAS and REGENERON PHARMACEUTICALS, INC. Dated as of July 1, 2015 CERTAIN PORTIONS OF THIS... (Filed With SEC on November 4, 2015)

IMMUNO-ONCOLOGY LICENSE AND COLLABORATION AGREEMENT By and Between SANOFI BIOTECHNOLOGY SAS and REGENERON PHARMACEUTICALS, INC. Dated as of July 1, 2015 CERTAIN PORTIONS OF THIS... (Filed With SEC on November 4, 2015)

AMENDMENT NO. 1 TO AMENDED AND RESTATED DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT (Filed With SEC on November 4, 2015)

AMENDMENT NO. 2 TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on November 4, 2015)

Date:August 5, 2015To:Regeneron Pharmaceuticals, Inc.777 Old Saw Mill River RoadTarrytown, NY 10591-6707Attention:Dominick AgronVP and Treasurer777 Old Saw Mill River... (Filed With SEC on November 4, 2015)

SEVENTEENTH AMENDMENT TO LEASE (Filed With SEC on November 4, 2015)

COLLABORATION AGREEMENT by and between REGENERON IRELAND and MITSUBISHI TANABE PHARMA CORPORATION CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR... (Filed With SEC on November 4, 2015)

TENTH AMENDMENT TO LEASE (Filed With SEC on August 4, 2015)

FOURTEENTH AMENDMENT TO LEASE (Filed With SEC on August 4, 2015)

FIFTEENTH AMENDMENT TO LEASE (Filed With SEC on August 4, 2015)

SIXTEENTH AMENDMENT TO LEASE (Filed With SEC on August 4, 2015)

FIRST AMENDMENT TO MT. PLEASANT LEASE (Filed With SEC on August 4, 2015)

Regeneron Pharmaceuticals, Inc. Cash Incentive Bonus Plan (Filed With SEC on June 17, 2015)

AMENDED AND RESTATED COLLABORATION AGREEMENT By and Between SANOFI-AVENTIS US, LLC and REGENERON PHARMACEUTICALS, INC. Dated as of February 23, 2015 TABLE OF CONTENTS (Filed With SEC on May 7, 2015)

RESTATED AMENDMENT AGREEMENT (Filed With SEC on February 12, 2015)

Annex A Unwind Period PriceAmendment Payment Amount per Warrant$370.00$273.46$375.00$278.44$380.00$283.43$385.00$288.41$390.00$293.40$395.00$298.38$397.75$301.07 (Filed With SEC on February 12, 2015)

Amendment, dated as of May 13, 2014, to the Master Terms and Conditions for Warrants, dated as of October 18, 2011, as supplemented by a confirmation dated October 18, 2011,... (Filed With SEC on August 5, 2014)

Amendment, dated as of May 14, 2014, to the Master Terms and Conditions for Warrants, dated as of October 18, 2011, as supplemented by a confirmation dated October 18, 2011,... (Filed With SEC on August 5, 2014)

Amendment, dated as of May 15, 2014, to the Master Terms and Conditions for Warrants, dated as of October 18, 2011, as supplemented by a confirmation dated October 18, 2011,... (Filed With SEC on August 5, 2014)

Amendment, dated as of May 16, 2014, to the Master Terms and Conditions for Warrants, dated as of October 18, 2011, as supplemented by a confirmation dated October 18, 2011,... (Filed With SEC on August 5, 2014)

REGENERON PHARMACEUTICALS, INC. Non-Qualified Stock Option OPTION AGREEMENT PURSUANT TO THE REGENERON PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN (Filed With SEC on June 18, 2014)

REGENERON PHARMACEUTICALS, INC. Incentive Stock Option OPTION AGREEMENT PURSUANT TO THE REGENERON PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN (Filed With SEC on June 18, 2014)

REGENERON PHARMACEUTICALS, INC. RESTRICTED STOCK AGREEMENT PURSUANT TO THE REGENERON PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN (Filed With SEC on June 18, 2014)

REGENERON PHARMACEUTICALS, INC. Non-Qualified Stock Option OPTION AGREEMENT PURSUANT TO THE REGENERON PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN (Non-Employee Director... (Filed With SEC on June 18, 2014)

AMENDMENT NO. 1 TO THE REGENERON PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED 2000 LONG-TERM INCENTIVE PLAN (Filed With SEC on February 13, 2014)

AMENDED AND RESTATED INVESTOR AGREEMENT By and Among SANOFI, SANOFI-AVENTIS US LLC, AVENTIS PHARMACEUTICALS INC., SANOFI-AVENTIS AMÉRIQUE DU NORD AND REGENERONPHARMACEUTICALS,... (Filed With SEC on January 13, 2014)

MT. PLEASANT LEASE by and between BMR-Landmark at Eastview LLC, a Delaware limited liability company and Regeneron Pharmaceuticals, Inc., a New York corporation (Filed With SEC on August 6, 2013)

ELEVENTH AMENDMENT TO LEASE (Filed With SEC on August 6, 2013)

TWELFTH AMENDMENT TO LEASE (Filed With SEC on August 6, 2013)

THIRTEENTH AMENDMENT TO LEASE (Filed With SEC on August 6, 2013)

FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on August 6, 2013)

[SANOFI LETTERHEAD] (Filed With SEC on August 6, 2013)

AMENDED AND RESTATED NON-EXCLUSIVE LICENSE AND SETTLEMENT AGREEMENT (Filed With SEC on August 6, 2013)

NON-EXCLUSIVE LICENSE AND SETTLEMENT AGREEMENT (Filed With SEC on August 6, 2013)

Annexe 1 (Filed With SEC on August 6, 2013)

AMENDMENT AGREEMENT (Filed With SEC on July 25, 2012)

[Shares Vest Type Full Vest Expiration Date [10 years from Grant** On Vest Date [__/__/__]** Date] [10 years from Grant** On Vest Date [__/__/__]** Date] [10 years from Grant** On... (Filed With SEC on February 21, 2012)

NON-EXCLUSIVE LICENSE AND PARTIALSETTLEMENT AGREEMENT (Filed With SEC on February 21, 2012)

EIGHTH AMENDMENT TO LEASE (Filed With SEC on October 27, 2011)

NINTH AMENDMENT TO LEASE (Filed With SEC on October 27, 2011)

REGENERON PHARMACEUTICALS, INC. 1.875% CONVERTIBLE SENIOR NOTES DUE 2016 PURCHASE AGREEMENT (Filed With SEC on October 24, 2011)

REGENERON PHARMACEUTICALS, INC. 1.875% CONVERTIBLE SENIOR NOTES DUE 2016 INDENTURE Dated as of October 21, 2011 WELLS FARGO BANK, NATIONAL ASSOCIATION Trustee (Filed With SEC on October 24, 2011)

REGENERON PHARMACEUTICALS, INC. 1.875% Convertible Senior Notes due 2016 (Filed With SEC on October 24, 2011)

MASTER TERMS AND CONDITIONS FOR CONVERTIBLE BONDHEDGING TRANSACTIONS BETWEEN GOLDMAN, SACHS & CO. AND REGENERON PHARMACEUTICALS, INC. (Filed With SEC on October 24, 2011)

MASTER TERMS AND CONDITIONS FOR BASE WARRANTS ISSUED BY REGENERON PHARMACEUTICALS, INC. (Filed With SEC on October 24, 2011)

MASTER TERMS AND CONDITIONS FOR CONVERTIBLE BONDHEDGING TRANSACTIONS BETWEEN CITIBANK, N.A. AND REGENERON PHARMACEUTICALS, INC. (Filed With SEC on October 24, 2011)

MASTER TERMS AND CONDITIONS FOR BASE WARRANTS ISSUED BY REGENERON PHARMACEUTICALS, INC. (Filed With SEC on October 24, 2011)

MASTER TERMS AND CONDITIONS FOR CONVERTIBLE BONDHEDGING TRANSACTIONS BETWEEN CREDIT SUISSE INTERNATIONAL AND REGENERON PHARMACEUTICALS, INC. (Filed With SEC on October 24, 2011)

MASTER TERMS AND CONDITIONS FOR BASE WARRANTS ISSUED BY REGENERON PHARMACEUTICALS, INC. (Filed With SEC on October 24, 2011)

MASTER TERMS AND CONDITIONS FOR CONVERTIBLE BONDHEDGING TRANSACTIONS BETWEEN MORGAN STANLEY & CO. INTERNATIONAL PLC AND REGENERON PHARMACEUTICALS, INC. (Filed With SEC on October 24, 2011)

MASTER TERMS AND CONDITIONS FOR BASE ADDITIONALWARRANTS ISSUED BY REGENERON PHARMACEUTICALS, INC. (Filed With SEC on October 24, 2011)

1 REGENERON PHARMACEUTICALS, INC. RESTRICTED STOCK AGREEMENT PURSUANT TO THE 2000 LONG-TERM INCENTIVE PLAN (Filed With SEC on February 17, 2011)

REGENERON PHARMACEUTICALS, INC. OPTION AGREEMENT PURSUANT TO THE 2000 LONG-TERM INCENTIVE PLAN (Filed With SEC on February 17, 2011)

SEVENTH AMENDMENT TO LEASE (Filed With SEC on February 17, 2011)

Amendment to the Non-Exclusive License and Material Transfer Agreement dated as of March 30, 2007 (Filed With SEC on October 28, 2010)

5,500,000 SHARES REGENERON PHARMACEUTICALS, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on October 13, 2010)

SIXTH AMENDMENT TOLEASE (Filed With SEC on July 28, 2010)

AMENDED AND RESTATEDDISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT By and Between AVENTIS PHARMACEUTICALSINC. and REGENERON PHARMACEUTICALS,INC. Dated as of November 10, 2009... (Filed With SEC on February 18, 2010)

AMENDED AND RESTATED LICENSE AND COLLABORATIONAGREEMENT By and Among AVENTIS PHARMACEUTICALS INC., SANOFI-AVENTIS AMERIQUE DUNORD and REGENERON PHARMACEUTICALS,INC. Dated as of... (Filed With SEC on February 18, 2010)

First Amendment to the InvestorAgreement dated as of December 20, 2007 (Filed With SEC on February 18, 2010)

IL-1 ANTIBODY TERMINATION AGREEMENT By and Between NOVARTIS PHARMA AG NOVARTIS PHARMACEUTICALS CORPORATION AND REGENERON PHARMACEUTICALS, INC. Dated as of June 8, 2009 (Filed With SEC on August 4, 2009)

TRAP -2 TERMINATION AGREEMENT By and Between NOVARTIS PHARMA AG NOVARTIS PHARMACEUTICALS CORPORATION AND REGENERON PHARMACEUTICALS, INC. Dated as of June 8, 2009 (Filed With SEC on August 4, 2009)

[Shares Vest Type Full Vest Expiration Date ** On Vest Date [__/__/__]** [10 years from Grant Date] ** On Vest Date [__/__/__]** [10 years from Grant Date] ** On Vest Date... (Filed With SEC on April 30, 2009)

REGENERON PHARMACEUTICALS,INC. OPTION AGREEMENT PURSUANT TO THE 2000 LONG-TERMINCENTIVE PLAN (Filed With SEC on April 30, 2009)

THIRD AMENDMENT TOLEASE (Filed With SEC on April 30, 2009)

REGENERON PHARMACEUTICALS,INC. CHANGE IN CONTROL SEVERANCEPLAN As amended and restated, effectiveNovember 14, 2008 INTRODUCTION (Filed With SEC on February 26, 2009)

EX-10.3: SECOND AMENDMENT TO LEASE (Filed With SEC on November 5, 2008)

EX-4.1: FORM OF CERTIFICATE OF SHARES OF COMMON STOCK (Filed With SEC on August 1, 2008)

EX-10.2: AMENDED AND RESTATED NON-EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on August 1, 2008)

EX-10.3: SUBSCRIPTION AGREEMENT (Filed With SEC on August 1, 2008)

REGENERON PHARMACEUTICALS, INC. (Filed With SEC on June 17, 2008)

DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT (Filed With SEC on February 27, 2008)

LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on February 27, 2008)

STOCK PURCHASE AGREEMENT (Filed With SEC on February 27, 2008)

INVESTOR AGREEMENT (Filed With SEC on February 27, 2008)

EX-10.1: FIRST AMENDMENT TO LEASE (Filed With SEC on November 7, 2007)

EX-10.1: NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENT (Filed With SEC on May 4, 2007)

EX-10.14: NON EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENT (Filed With SEC on March 12, 2007)

7,600,000 SHARES REGENERON PHARMACEUTICALS, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on November 16, 2006)

EX-10.1: LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on November 6, 2006)

EX-10.13.3: AMENDMENT NO. 3 TO COLLABORATION AGREEMENT (Filed With SEC on February 28, 2006)

EX-10.13.4: AMENDMENT NO. 4 TO COLLABORATION AGREEMENT (Filed With SEC on February 28, 2006)

EX-10.1: CHANGE IN CONTROL SEVERANCE PLAN (Filed With SEC on January 25, 2006)

EX-10.01: FORM OF OPTION AGREEMENT (Filed With SEC on December 16, 2005)

EX-10.02: FORM OF OPTION AGREEMENT (Filed With SEC on December 16, 2005)

EX-10.10.1: AMENDMENT AND AGREEMENT (Filed With SEC on August 8, 2005)

AMENDMENT #1 TO MANUFACTURING AGREEMENT (Filed With SEC on March 11, 2005)

AMENDMENT #2 TO MANUFACTURING AGREEMENT (Filed With SEC on March 11, 2005)

AMENDMENT #3 TO MANUFACTURING AGREEMENT (Filed With SEC on March 11, 2005)

AMENDMENT #4 TO MANUFACTURING AGREEMENT (Filed With SEC on March 11, 2005)

AMENDMENT #5 TO MANUFACTURING AGREEMENT (Filed With SEC on March 11, 2005)

EMPLOYMENT AGREEMENT (Filed With SEC on March 11, 2005)

AMENDMENT NO. 1 TO COLLABORATION AGREEMENT (Filed With SEC on March 11, 2005)

SECOND AMENDMENT TO COLLABORATION AGREEMENT (Filed With SEC on January 11, 2005)

FORM OF OPTION AGREEMENT (Filed With SEC on December 13, 2004)

FORM OF RESTRICTED STOCK AWARD AGREEMENT (Filed With SEC on December 13, 2004)

AMENDMENT NO.3 TO INCENTIVE PLAN (Filed With SEC on August 5, 2004)

COLLABORATION AGREEMENT (Filed With SEC on November 12, 2003)

STOCK PURCHASE AGREEMENT (Filed With SEC on November 12, 2003)

NON-EXCLUSIVE PATENT LICENSE AGREEMENT (Filed With SEC on November 12, 2003)

COLLABORATION, LICENSE AND OPTION AGREEMENT (Filed With SEC on May 15, 2003)

STOCK PURCHASE AGREEMENT (Filed With SEC on May 15, 2003)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 15, 2003)

EX-10.6.1 AMENDMENT #1 TO LONG TERM INCENTIVE PLAN (Filed With SEC on March 31, 2003)

EX-10.6.2 AMENDMENT #2 TO LONG TERM INCENTIVE PLAN (Filed With SEC on March 31, 2003)

EX-10.18 EMPLOYMENT AGREEMENT (Filed With SEC on March 31, 2003)

EX-10.22: FOCUSED COLLABORATION AGREEMENT (Filed With SEC on August 13, 2002)

LICENSE AGREEMENT (Filed With SEC on August 13, 2002)

CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORP (Filed With SEC on March 22, 2002)

2000 LONG-TERM INCENTIVE PLAN (Filed With SEC on March 22, 2002)

Category

Industry

Companies

Contracts

Regeneron Pharmaceuticals Contracts & Agreements